Jefferies initiated coverage on Allurion Technologies with a new price target

Meeting to Now be Held on Thursday, April 10, 2025 at 12:00 pm Via Live Audio Webcast Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that its Special Meeting of Stockholders (the "Special Meeting"), originally scheduled for Friday, April 4, 2025, has been postponed. The Special Meeting is now scheduled to be held on Thursday, April 10, 2025 at 12:00 p.m. (Eastern Time) and will still be held virtually via live audio webcast at www.virtualshareholdermeeting.com/ALUR2025SM. The record date for the Special Meeting, March 14, 2025, remains unchanged and applies to the postponed Special Meeting. The Special Meeting

Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. Recent Company Highlights and Outlook Reported initial data on the combination of the Allurion Program with low-dose GLP-1s showing optimization of muscle mass and GLP-1 adherence and announced plans to perform additional prospective studies on the combination approach Fourth quarter 2024 revenue of $5.6 million and full year revenue of $32.1 million, consistent with preannouncement on January 14, 2025 Fourth quarter 2024 operating expenses of $19

Average Total Weight Loss of 20% With 15% Increase in Lean Body Mass After 8 Months of Combined Therapy Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimize muscle mass and GLP-1 adherence. 52 patients treated with the Allurion Balloon were started on 0.25mg semaglutide after completing their first month of balloon therapy. The dose of semaglutide was increased to no greater than 1.0mg over the subsequent 6 months. After 8 months of this combination approach, average total body weight loss was 20.3%, and lean body mass

Chardan Capital Markets downgraded Allurion Technologies from Buy to Neutral

TD Cowen initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $2.00

ROTH MKM initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $2.00

4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

SCHEDULE 13D/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

Mr. Johns has worked over two decades bringing leading GLP-1 weight loss drugs and other metabolic drugs to market Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Keith Johns to its Board of Directors effective September 2, 2024. "We are extremely excited to welcome Keith to the Allurion Board of Directors as we look to capitalize on the significant opportunity in front of us within the fast-growing obesity management space," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "I believe having Keith as a sounding board as we leverage the opportunities created by GLP-1s will be a competitive advantage." Omar Ishrak, Al

Mr. Wild brings over 20 years of experience building profitable commercial organizations at leading healthcare brands Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Adrian Wild as SVP, International Commercial. Effective August 13, 2024, Mr. Wild assumed the role and will lead the Company's international commercial sales and operations functions. "We are thrilled to welcome Adrian to Allurion and add his expertise to our leadership team as we advance the company toward profitability," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "Adrian joins us at an extremely important time – where the obesity market is expandi

Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Ojas A. Buch as its new Chief Operating Officer. Effective June 3, 2024, Ojas assumed the role of Chief Operating Officer and will lead the company's Research and Development, Manufacturing and Operations, Quality and Regulatory, and Business Development and Innovation functions. He will also play a crucial role in commercial functions while working closely with the Board and Executive Leadership Team. Ojas will provide strategic and execution-focused guidance aimed to help the company achieve major milestones and scale sustainably. With a 25-year track record in the health

Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. Recent Company Highlights and Outlook Reported initial data on the combination of the Allurion Program with low-dose GLP-1s showing optimization of muscle mass and GLP-1 adherence and announced plans to perform additional prospective studies on the combination approach Fourth quarter 2024 revenue of $5.6 million and full year revenue of $32.1 million, consistent with preannouncement on January 14, 2025 Fourth quarter 2024 operating expenses of $19

Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that it will report financial results for the fourth quarter 2024 on Wednesday, March 26, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (international) and use Conference ID 1905455. To listen to the conference call via live audio webcast, please visit the Events section of Allurion's Investor Relations website at Allurion - Events & Presentations. A replay of the confer

Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced its financial results for the third quarter ended September 30, 2024 and provided a business update. Recent Company Highlights Revenue of $5.4 million, which includes a reduction of $1.2 million for product recalled from France during the third quarter AI product revenue in the third quarter from the Virtual Care Suite (VCS) grew by 82% versus prior year as first patients in the United States treated with GLP-1s were on-boarded Last patient in AUDACITY FDA clinical trial successfully exited, putting top-line readout on track for the end of the year Work

SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

SC 13D/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)